Sphero

Spero Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing a novel pipeline of antibiotics for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for complicated urinary tract infections (cUTI) through a significant strategic partnership with GSK. Spero is also advancing SPR720, an oral treatment for nontuberculous mycobacterial (NTM) lung disease, and SPR206, a next-generation polymyxin for serious Gram-negative infections. By focusing on high-unmet-need areas in the anti-infective space, Spero aims to provide clinicians with effective oral and intravenous options to combat the global rise of antimicrobial resistance.